New treatment for lazy eye

New treatment for lazy eye
Howard Larkin
Howard Larkin
Published: Saturday, November 14, 2015

 A new study on lazy eye has  found that programmable electronic glasses help improve vision in children just as well as the more traditional treatment using eye patches. This “digital patch” is the first new effective treatment for lazy eye in half a century , according to the results from the first U.S. trial of the device presented at AAO 2015, the 119th Annual Meeting of the American Academy of Ophthalmology.

The electronic glasses used in this study combine vision correction and occlusion. The lenses can be filled to fit a child’s vision prescription. Because the lenses are liquid crystal display (LCD), they can also be programmed to turn opaque, occluding vision in the left or right eye for different time intervals, acting like a digital patch that flickers on and off.

Researchers at the Glick Eye Institute at Indiana University recently tested the effectiveness of occlusion glasses compared to patching in a randomized clinical study. They recruited 33 subjects with lazy eye between age 3 and 8 who wore spectacles to correct their vision. One group wore an adhesive patch for two hours daily. The other wore Amblyz™ occlusion glasses for 4 hours daily. In the study, the lens over the lazy eye switched from clear to opaque every 30 seconds. After three months, both groups of children showed the same amount of improvement in the lazy eye, gaining two lines on a reading chart. 

“When you talk to adults who underwent childhood treatment for amblyopia, they will tell you that wearing a patch was the worst thing ever,” said Daniel Neely, M.D., a pediatric ophthalmology professor at Indiana University who led the study. “With these electronic occlusion glasses, the child learns that the lens will be clear again in just a few seconds so they may be more cooperative with the treatment. For parents who have struggled with drops and patching, this could be a great alternative.”

The U.S. Food and Drug Administration has approved the Amblyz occlusion glasses as a medical device. They are available in the United States from eye care professionals for around $450.

Latest Articles
Nutrition and the Eye: A Recipe for Success

A look at the evidence for tasty ways of lowering risks and improving ocular health.

Read more...

New Award to Encourage Research into Sustainable Practices

Read more...

Sharing a Vision for the Future

ESCRS leaders update Trieste conference on ESCRS initiatives.

Read more...

Extending Depth of Satisfaction

The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.

Read more...

Conventional Versus Laser-Assisted Cataract Surgery

Evidence favours conventional technique in most cases.

Read more...

AI Scribing and Telephone Management

Automating note-taking and call centres could boost practice efficiency.

Read more...

AI Analysis and the Cornea

A combination of better imaging and AI deep learning could significantly improve corneal imaging and diagnosis.

Read more...

Cooking a Feast for the Eyes

A cookbook to promote ocular health through thoughtful and traditional cuisine.

Read more...

Need to Know: Spherical Aberration

Part three of this series examines spherical aberration and its influence on higher-order aberrations.

Read more...

Generating AI’s Potential

How generative AI impacts medicine, society, and the environment.

Read more...